Pulmonary hypertension in bronchopulmonary dysplasia

Sara K. Berkelhamer, Karen K. Mestan, Robin H Steinhorn

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

Pulmonary hypertension (PH) is a common complication of neonatal respiratory diseases, including bronchopulmonary dysplasia (BPD), and recent studies have increased awareness that PH worsens the clinical course, morbidity and mortality of BPD. Recent evidence indicates that up to 18% of all extremely low-birth-weight infants will develop some degree of PH during their hospitalization, and the incidence rises to 25-40% of the infants with established BPD. Risk factors are not yet well understood, but new evidence shows that fetal growth restriction is a significant predictor of PH. Echocardiography remains the primary method for evaluation of BPD-associated PH, and the development of standardized screening timelines and techniques for identification of infants with BPD-associated PH remains an important ongoing topic of investigation. The use of pulmonary vasodilator medications, such as nitric oxide, sildenafil, and others, in the BPD population is steadily growing, but additional studies are needed regarding their long-term safety and efficacy.

Original languageEnglish (US)
Pages (from-to)124-131
Number of pages8
JournalSeminars in Perinatology
Volume37
Issue number2
DOIs
StatePublished - Apr 2013

Keywords

  • Chronic lung disease
  • Fetal growth restriction
  • Prematurity
  • Pulmonary vascular disease
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Pulmonary hypertension in bronchopulmonary dysplasia'. Together they form a unique fingerprint.

Cite this